H.R. 9077: To direct the Director of the National Institutes of Health and the Secretary of Health and Human Services to evaluate hormone variability and hormone testing, respectively, in women with respect to perimenopause.
Sponsors
1 sponsor
Actions
2 actions
| Date | Action |
|---|---|
| May. 29, 2026 | Introduced in House |
| May. 29, 2026 | Referred to the House Committee on Energy and Commerce. |
Corporate Lobbying
0 companies lobbying
None found.
* Note that there can be significant delays in lobbying disclosures, and our data may be incomplete.
Potentially Relevant Congressional Stock Trades
No relevant congressional stock trades found.